Research to be presented concerning Bexxar® at the American Society of Hematology Annual Meeting

December 11, 2001

Eash poster or oral is embargoed until it is actually presented.

Research to be presented concerning Bexxar® (Tositumomab and Iodine I 131 Tositumomab) an investigational radioimmunotherapy being studied for the treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) includes:

Contact: Julie McQuain (212) 477-0472

Sunday, December 9, 2001

[1433] Acute and Delayed Hematologic Toxicities Associated with Bexxar® Therapy Are Modest: Overall Experience in Patients with Low-Grade and Transformed Low-Grade NHL.
Date: Sunday, December 9, 2001 Time: 10:00 am Location: Hall C,
Poster Board Number 538

Monday, December 10, 2001

[2527] Bexxar® (Tositumomab and Iodine I 131 Tositumomab) Results in Durable Long-Term Responses in Patients with Poor Prognosis, Multiple Relapsed (Rel), and Refractory (Ref) Low-Grade or Transformed Low-Grade Non-Hodgkins Lymphoma (NHL).
Date: Monday, December 10, 2001 Time: 10:00 am Location: Hall C,
Poster Board Number 512

Tuesday, December 11, 2001

[3503] Results of a Randomized Study of Bexxar® (Tositumomab and Iodine I 131 Tositumomab) vs. Unlabeled Tositumomab in Patients with Relapsed or Refractory Low-Grade or Transformed Non-Hodgkin's Lymphoma (NHL).
Date: Tuesday, December 11, 2001 Time: 8:45 am Location: Hall F-5

[3505] Triple Modality Therapy for Follicular Low-Grade Lymphoma: Initial Treatment with Fludarabine Followed by Bexxar® (Tositumomab and Iodine I 131 Tositumomab).
Date: Tuesday, December 11, 2001 Time 9:15 am Location: Hall F-5

JMPR Associates, Inc.

Related Lymphoma Articles from Brightsurf:

Oncotarget: An integrative microenvironment approach for follicular lymphoma
Oncotarget Volume 11, Issue 33 features Figure 8, ''Haplotype estimates in follicular lymphoma patients,'' by Assis-Mendonça, et al. which reported that the authors tested associations between SNPs, clinicopathological features and TME composition, and proposed survival models in R-CHOP/R-CVP-treated patients.

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

A new immunotherapeutic agent for children and adolescents with advanced lymphoma
The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine.

Lymphoma's different route revealed
Researchers at the MDC observe the very early stages of blood vessel development in lymph node tumors.

Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma
Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-Cell Receptor Signaling.

Suspect eliminated as a therapeutic target in B cell lymphoma
Australian researchers have narrowed the focus on which survival proteins are important for the survival of B cell lymphomas, eliminating the protein BCL-W from the 'suspect list'.

New factor in the development of childhood lymphoma
The immune system is highly complex and a detailed understanding of many underlying mechanisms is still lacking.

Antibiotics can inhibit skin lymphoma
New research from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma.

Association of BRCA2 mutations with risk of childhood lymphoma
This research letter reports on the association of BRCA2 gene mutations and potential risk for pediatric or adolescent lymphoma.

Why Hodgkin's lymphoma cells grow uncontrollably
Although classical Hodgkin's lymphoma is generally easily treatable today, many aspects of the disease still remain a mystery.

Read More: Lymphoma News and Lymphoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to